Eosinophilic Esophagitis: Navigating the Challenges and Opportunities in Clinical Trials

The diagnostic odyssey

Eosinophilic esophagitis (EoE) presents a significant diagnostic challenge for both patients and healthcare providers. This chronic immune-mediated condition is characterized by eosinophilic inflammation of the esophagus, leading to symptoms such as dysphagia, food impaction, and chest pain. The journey to diagnosis often involves multiple healthcare encounters, extensive testing, and sometimes years of trial and error, contributing to a substantial burden of disease for patients. The complexity of EoE's presentation and the overlap with other gastrointestinal disorders complicate the identification of eligible patients for clinical trials, as many may remain undiagnosed or misdiagnosed.

The trial landscape right now

Currently, there are 8 recruiting clinical trials focused on Eosinophilic Esophagitis across 47 sites in 9 countries. The trials span various phases, including 6 that do not specify a phase, 1 in Phase I, and 1 in Phase III. Leading sponsors include notable institutions such as Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), Eupraxia Pharmaceuticals Inc., and Dr. Falk Pharma GmbH, among others. The top geographical locations include the United States with 24 sites, followed by Australia with 6 sites, and the United Kingdom and Canada, each with 4 sites.

For example, NCT03312686 investigates changes in esophageal distensibility with proton pump inhibitors in patients with esophageal eosinophilia, while NCT05608681 evaluates EP-104GI in adults with EoE. Another significant study, NCT06596252, is a Phase III trial comparing once daily versus twice daily budesonide orodispersible tablets for the induction of remission in EoE. These trials represent a crucial step in advancing the understanding and treatment of EoE, but the challenge of identifying eligible patients remains.

How we detect the match

Innovative approaches to patient identification are essential for improving trial enrollment and patient outcomes in Eosinophilic Esophagitis. By leveraging an HL7/FHIR + AI layer, healthcare systems can streamline the patient identification process, significantly reducing the need for manual chart reviews. This technology utilizes specific FHIR resources, such as Condition, Observation, MedicationRequest, and DiagnosticReport, to detect relevant signals in existing clinical data.

For instance, conditions coded with ICD-10 related to EoE, alongside laboratory observations indicating eosinophilia, can be automatically flagged through computable phenotypes. This allows for a more efficient and accurate identification of eligible patients who may benefit from clinical trials. As a result, healthcare providers can better match patients with appropriate studies, enhancing the likelihood of successful enrollment.

Beyond the trial: better care

The integration of HL7/FHIR + AI not only aids in trial enrollment but also shortens the diagnostic odyssey for patients with Eosinophilic Esophagitis. By improving the coordination and monitoring of patient care, healthcare systems can facilitate earlier diagnosis and more timely treatment interventions, regardless of whether a patient enrolls in a clinical trial.

For example, tracking medication adherence through MedicationRequest resources can help identify patients who may be struggling with treatment compliance, enabling targeted interventions. Furthermore, the use of DiagnosticReport resources can facilitate more efficient follow-ups and monitoring of disease progression, ultimately leading to improved patient outcomes and quality of life.

The takeaway

Eosinophilic Esophagitis remains a challenging condition, but recent advancements in clinical trial landscapes and patient identification methods offer hope for improved outcomes. By harnessing the power of integration technologies, healthcare providers can enhance patient care, streamline trial enrollment, and ultimately contribute to a deeper understanding of this complex disease.